ES2530872T3 - Organos y células modificados para xenotrasplante - Google Patents

Organos y células modificados para xenotrasplante Download PDF

Info

Publication number
ES2530872T3
ES2530872T3 ES02766869T ES02766869T ES2530872T3 ES 2530872 T3 ES2530872 T3 ES 2530872T3 ES 02766869 T ES02766869 T ES 02766869T ES 02766869 T ES02766869 T ES 02766869T ES 2530872 T3 ES2530872 T3 ES 2530872T3
Authority
ES
Spain
Prior art keywords
xenotransplantation
organs
cells modified
cells
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02766869T
Other languages
English (en)
Inventor
Alex Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RBC Biotechnology Inc
Original Assignee
RBC Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RBC Biotechnology Inc filed Critical RBC Biotechnology Inc
Application granted granted Critical
Publication of ES2530872T3 publication Critical patent/ES2530872T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para obtener un órgano, tejido o células porcinos modificados que son resistentes a rechazo mediado por anticuerpo preformado tras el trasplante a un ser humano, que comprende derivar las células, el tejido o el órgano de un cerdo que se ha modificado por ingeniería genética para evitar la expresión de CMP-ácido Nacetilneuramínico hidroxilasa y para evitar la expresión de α-1,3-galactosiltransferasa.
ES02766869T 2001-04-30 2002-04-29 Organos y células modificados para xenotrasplante Expired - Lifetime ES2530872T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28768401P 2001-04-30 2001-04-30
US30060401P 2001-06-22 2001-06-22
US33387601P 2001-11-28 2001-11-28
PCT/US2002/013564 WO2002088351A1 (en) 2001-04-30 2002-04-29 Modified organs and cells for xenotransplantation

Publications (1)

Publication Number Publication Date
ES2530872T3 true ES2530872T3 (es) 2015-03-06

Family

ID=27403740

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02766869T Expired - Lifetime ES2530872T3 (es) 2001-04-30 2002-04-29 Organos y células modificados para xenotrasplante

Country Status (7)

Country Link
US (3) US7166278B2 (es)
EP (1) EP1383889B1 (es)
JP (1) JP2004533242A (es)
AU (1) AU2002308533B2 (es)
CA (1) CA2445945A1 (es)
ES (1) ES2530872T3 (es)
WO (1) WO2002088351A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528500A1 (en) * 2003-06-06 2004-12-16 University Of Pittsburgh Porcine cmp-n-acetylneuraminic acid hydroxylase gene
CA2533259C (en) * 2003-07-21 2014-01-28 Lifecell Corporation Acellular tissue matrices made from galactose .alpha.-1,3-galactose-deficient tissue
DK1734814T3 (en) * 2004-03-17 2015-04-07 Revivicor Inc Tissue DERIVED FROM ANIMALS IS MISSING ANY EXPRESSION OF FUNCTIONAL ALPHA-1,3 galactosyltransferase
JP2006129736A (ja) * 2004-11-02 2006-05-25 Nippon Dobutsu Kogaku Kenkyusho:Kk 異種移植用豚細胞、その選抜方法及び異種移植用豚
US20060147429A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
US20070010897A1 (en) * 2005-01-06 2007-01-11 Stone Kevin R Immunochemically modified and sterilized xenografts and allografts
WO2006133356A2 (en) 2005-06-08 2006-12-14 The Regents Of The University Of California Elimination of n-glycolylneuraminic acid from mammalian products for human use
FI20055398A0 (fi) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
FI20075030A0 (fi) 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Menetelmä solujen modifioimiseksi
WO2009069986A2 (en) * 2007-11-30 2009-06-04 Korea Research Institute Of Bioscience And Biotechnology Genetically-modified cell line for producing cloned miniature pigs for xenotransplantation and method for preparing the same.
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
CN102197131A (zh) * 2008-09-09 2011-09-21 加利福尼亚大学董事会 通过代谢竞争除去污染性的非人唾液酸
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
KR101276801B1 (ko) * 2011-01-21 2013-06-19 한화엘앤씨 주식회사 ｓＴＮＦＲ1-Ｆｃ 유전자를 발현하는 형질전환 돼지 및 이의 용도
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US20140115728A1 (en) 2012-10-24 2014-04-24 A. Joseph Tector Double knockout (gt/cmah-ko) pigs, organs and tissues
ES2846758T3 (es) 2013-11-04 2021-07-29 Lifecell Corp Métodos para eliminar la alfa-galactosa
CA2965550A1 (en) 2014-10-22 2016-04-28 Indiana University Research & Technology Corporation Triple transgenic pigs suitable for xenograft
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3229586B1 (en) 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE
EP3612023A4 (en) 2017-04-20 2021-05-12 Egenesis, Inc. METHOD FOR PRODUCING GENETICALLY MODIFIED ANIMALS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03255028A (ja) * 1990-03-01 1991-11-13 Imeeji Meekaa:Kk 免疫抑制剤
WO1992017189A1 (en) * 1991-03-29 1992-10-15 The Regents Of The University Of California Gangliosides with immunosuppressive activity
US6228631B1 (en) 1992-10-22 2001-05-08 New York Blood Center, Inc. Recombinant α-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
US5330974A (en) * 1993-03-01 1994-07-19 Fibratek, Inc. Therapeutic fibrinogen compositions
US6331658B1 (en) * 1993-04-20 2001-12-18 Integris Baptist Medical Center, Inc. Genetically engineered mammals for use as organ donors
JPH09508277A (ja) 1994-01-27 1997-08-26 ブレサゲン リミテッド ヒト異種移植における超急性拒絶の管理のための物質及び方法
US6166288A (en) * 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
US6245890B1 (en) 1999-03-26 2001-06-12 New York Blood Center, Inc. Porcine protein and uses thereof

Also Published As

Publication number Publication date
US20030165480A1 (en) 2003-09-04
JP2004533242A (ja) 2004-11-04
CA2445945A1 (en) 2002-11-07
EP1383889B1 (en) 2014-11-19
EP1383889A1 (en) 2004-01-28
US7166278B2 (en) 2007-01-23
AU2002308533B2 (en) 2007-07-19
US20070089178A1 (en) 2007-04-19
WO2002088351A1 (en) 2002-11-07
EP1383889A4 (en) 2005-01-26
US8034330B2 (en) 2011-10-11
US20110301341A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
DE60121450D1 (de) Mittels gewebetechnologie hergestellte dezellularisierte gegenstände und gewebe
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
DOP2001000321A (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina.
EP1928519A4 (en) Decellularization and recellularization of organs and tissues
PT1404811E (pt) O monóxido de carbono melhora os resultados nos transplantes de tecidos e de orgãos e suprime a apoptose
DE50005104D1 (de) Biologisches gelenkkonstrukt
DK0621766T3 (da) Hornhindeækvivalent-in-vitro-model
DE60330468D1 (de) Schweine ohne jegliche expression funktioneller alpha-1,3-galactosyltransferase
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
MXPA02007137A (es) Fuente de tejido hepatico.
DE60140200D1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
DE502004012226D1 (de) Saugstent
DE502005006732D1 (de) Implantat für den chirurgischen Einsatz bei Menschen oder Wirbeltieren
PE20060507A1 (es) Composicion farmaceutica que contiene acido micofenolico con recubrimiento de liberacion modificada
WO2006093857A3 (en) Method of providing readily available cellular material derived from peripheral blood and a composition thereof
CY1111368T1 (el) Προαγγειοποιημενα μοσχευματα ιστου για την αναδομηση ενος ανθρωπινου ή ζωικου οργανου
ATE525091T1 (de) Zusammensetzungen und verfahren zur regulierten proteinexpression im darm
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
ATE489963T1 (de) Chaperonin-10-immunosuppression
AU5380201A (en) Method for expansion of epithelial stem cells
FR2872431B1 (fr) Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
WO2006093860A3 (en) Method and composition for repairing heart tissue
BR0207434A (pt) Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos